The Prospects of the Two-Day Cardiopulmonary Exercise Test (CPET) in ME/CFS Patients: A Meta-Analysis.
Lim, Eun-Jin, Kang, Eun-Bum, Jang, Eun-Su et al. · Journal of clinical medicine · 2020 · DOI
Quick Summary
Researchers reviewed studies testing a two-day exercise test (called CPET) that might help diagnose ME/CFS by measuring how the body performs differently on day two compared to day one. In ME/CFS patients, performance dropped on day two, while it improved in healthy people—suggesting this test could objectively measure the characteristic crash (postexertional malaise) that follows exertion in ME/CFS. The test showed promise, but more large-scale studies are needed before it can be used clinically.
Why It Matters
ME/CFS lacks objective diagnostic biomarkers, making diagnosis difficult and delaying patient care. If validated, the two-day CPET could provide physicians with an objective test to confirm ME/CFS and document PEM—the hallmark symptom—potentially improving diagnostic accuracy and standardizing clinical assessment across different medical centers.
Observed Findings
All four measured parameters (VO₂peak, Workload peak, VO₂@VT, Workload@VT) were lower on day two compared to day one in ME/CFS patients.
In healthy controls, all parameters increased or remained stable from day one to day two.
Workload@VT showed the most significant difference between ME/CFS patients and controls, with changes of -10.8 on test one versus -33.0 on test two (p<0.05).
The pattern of declining performance on day two was consistent across ME/CFS patient groups in reviewed studies.
Inferred Conclusions
The two-day CPET demonstrates potential as an objective measure of postexertional malaise in ME/CFS patients.
The reciprocal response pattern (decline in patients vs. improvement in controls) suggests the test could differentiate ME/CFS from other conditions and general deconditioning.
Workload@VT may be the most sensitive parameter for detecting PEM-related functional impairment.
Larger, well-controlled clinical trials comparing ME/CFS to other fatiguing disorders are necessary before clinical implementation.
Remaining Questions
Can the two-day CPET reliably distinguish ME/CFS from other post-viral fatigue conditions, major depression, and other fatigue-related disorders?
What This Study Does Not Prove
This meta-analysis does not establish the two-day CPET as a validated diagnostic tool; it demonstrates only proof-of-concept potential. The study does not prove the test can distinguish ME/CFS from other fatiguing illnesses like depression or other post-viral conditions, nor does it confirm whether observed declines are specific to PEM versus general deconditioning or other mechanisms.
What is the optimal exercise intensity and duration for the CPET protocol, and does standardization across sites affect test reliability?
Do improvements in two-day CPET performance correlate with clinical recovery, and can it be used to monitor treatment response?
What physiological mechanisms underlie the differential day-two response in ME/CFS patients—mitochondrial dysfunction, viral persistence, autonomic dysfunction, or other factors?